RU95115405A - HUMANIZED IMMUNOGLOBULINS, COMPOSITION, RECOMBINANT IMMUNOGLOBULINS, METHOD OF TREATMENT - Google Patents
HUMANIZED IMMUNOGLOBULINS, COMPOSITION, RECOMBINANT IMMUNOGLOBULINS, METHOD OF TREATMENTInfo
- Publication number
- RU95115405A RU95115405A RU95115405/14A RU95115405A RU95115405A RU 95115405 A RU95115405 A RU 95115405A RU 95115405/14 A RU95115405/14 A RU 95115405/14A RU 95115405 A RU95115405 A RU 95115405A RU 95115405 A RU95115405 A RU 95115405A
- Authority
- RU
- Russia
- Prior art keywords
- immunoglobulin
- heavy
- human
- humanized
- variable region
- Prior art date
Links
- 102000018358 Immunoglobulins Human genes 0.000 title claims 58
- 108060003951 Immunoglobulins Proteins 0.000 title claims 58
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 title 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 11
- 230000000875 corresponding Effects 0.000 claims 11
- 102000004965 antibodies Human genes 0.000 claims 10
- 108090001123 antibodies Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 102000016551 L-Selectin Human genes 0.000 claims 6
- 108010092694 L-Selectin Proteins 0.000 claims 6
- 230000027455 binding Effects 0.000 claims 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 125000004429 atoms Chemical group 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 206010022114 Injury Diseases 0.000 claims 2
- 102000003800 Selectins Human genes 0.000 claims 2
- 108090000184 Selectins Proteins 0.000 claims 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000002889 Endothelial Cells Anatomy 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 210000000440 Neutrophils Anatomy 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229960000103 thrombolytic agents Drugs 0.000 claims 1
Claims (29)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98394692A | 1992-12-01 | 1992-12-01 | |
US07/983,946 | 1992-12-01 | ||
US07/983.946 | 1992-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95115405A true RU95115405A (en) | 1998-01-10 |
RU2151612C1 RU2151612C1 (en) | 2000-06-27 |
Family
ID=25530200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95115405/14A RU2151612C1 (en) | 1992-12-01 | 1993-11-30 | Human immunoglobulin showing specificity to human protein l-selectin |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0671951A4 (en) |
JP (1) | JPH08503617A (en) |
KR (1) | KR100371784B1 (en) |
AU (1) | AU689090B2 (en) |
CA (1) | CA2149025A1 (en) |
CZ (1) | CZ140195A3 (en) |
FI (1) | FI952658A0 (en) |
HU (1) | HUT71790A (en) |
NO (1) | NO952160L (en) |
PL (1) | PL309249A1 (en) |
RU (1) | RU2151612C1 (en) |
WO (1) | WO1994012215A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6010861A (en) * | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
AU6155896A (en) * | 1995-06-07 | 1996-12-30 | Cytel Corporation | Humanized antibodies to e-selectin |
PL187090B1 (en) * | 1995-08-17 | 2004-05-31 | Protein Design Labs | Anti-selecting antibodies for preventing a multiorgan insufficiency caused by a multiorgan lesion and for prewventing actue multiorgan lesions resulting from appliance of extracorporeal circulation |
AU746888B2 (en) * | 1995-08-17 | 2002-05-02 | Protein Design Labs, Inc. | Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage |
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
JP2001501612A (en) * | 1996-09-27 | 2001-02-06 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Methods for treating ischemic disease and improving post-stroke symptoms |
EP0852951A1 (en) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
WO1999043353A2 (en) * | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
US20020029391A1 (en) * | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
UY28886A1 (en) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18 |
IN2014DN10515A (en) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
KR20150091545A (en) | 2006-06-08 | 2015-08-11 | 추가이 세이야쿠 가부시키가이샤 | Preventive or remedy for inflammatory disease |
RU2510400C9 (en) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr |
MX2010003450A (en) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region. |
CN104162155A (en) | 2007-12-05 | 2014-11-26 | 中外制药株式会社 | Therapeutic agent for pruritus |
ES2834741T3 (en) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anti-NR10 antibody and its use |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
KR20160062207A (en) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | Anti-NR10 antibody and use thereof |
JP2010210772A (en) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | Method of manufacturing liquid crystal display device |
EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
TWI682995B (en) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | Antibody constant region alteration |
DK2597945T3 (en) * | 2010-07-26 | 2020-09-21 | Trianni Inc | Transgenic animals and methods for their use |
EP2947151A1 (en) | 2010-08-02 | 2015-11-25 | Regeneron Pharmaceuticals, Inc. | Binding proteins comprising vl domains |
JP6030452B2 (en) | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | Antigen-binding molecules that repeatedly bind to multiple molecules of antigen |
EP2654781B1 (en) * | 2010-12-21 | 2018-01-24 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
DK2738259T3 (en) | 2011-02-25 | 2020-02-17 | Regeneron Pharma | ADAM6 mice |
PT3572517T (en) | 2011-08-05 | 2021-06-23 | Regeneron Pharma | Humanized universal light chain mice |
TR201903439T4 (en) | 2011-12-20 | 2019-04-22 | Regeneron Pharma | Humanized light chain mice. |
RS62121B1 (en) | 2012-06-12 | 2021-08-31 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
AU2015231025A1 (en) | 2014-03-21 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
WO2016149678A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
TW202327654A (en) | 2015-04-14 | 2023-07-16 | 日商中外製藥股份有限公司 | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient |
BR112022006590A2 (en) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | PREPARATION CONTAINING ANTIBODIES |
WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
-
1993
- 1993-11-30 EP EP94903357A patent/EP0671951A4/en not_active Withdrawn
- 1993-11-30 RU RU95115405/14A patent/RU2151612C1/en not_active IP Right Cessation
- 1993-11-30 CZ CZ951401A patent/CZ140195A3/en unknown
- 1993-11-30 WO PCT/US1993/011612 patent/WO1994012215A1/en not_active Application Discontinuation
- 1993-11-30 JP JP6513460A patent/JPH08503617A/en not_active Ceased
- 1993-11-30 CA CA002149025A patent/CA2149025A1/en not_active Abandoned
- 1993-11-30 KR KR1019950702196A patent/KR100371784B1/en not_active IP Right Cessation
- 1993-11-30 AU AU57327/94A patent/AU689090B2/en not_active Ceased
- 1993-11-30 HU HU9501564A patent/HUT71790A/en unknown
- 1993-11-30 PL PL93309249A patent/PL309249A1/en unknown
-
1995
- 1995-05-31 FI FI952658A patent/FI952658A0/en not_active IP Right Cessation
- 1995-05-31 NO NO952160A patent/NO952160L/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95115405A (en) | HUMANIZED IMMUNOGLOBULINS, COMPOSITION, RECOMBINANT IMMUNOGLOBULINS, METHOD OF TREATMENT | |
DE69636748T2 (en) | BIS-SPECIFIC ANTIBODY FOR THE EFFECTIVE TREATMENT OF B-CELL LYMPHOMES AND CELL LINES | |
KR970700513A (en) | HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4 Against Leukocyte Adhesion Molecule VLA-4 | |
DE69233192T2 (en) | HUMANIZED ANTIBODY AGAINST CD18 | |
AU764211B2 (en) | Humanized antibodies to gamma-interferon | |
DE69532889T2 (en) | INTERLEUKIN-5 SPECIFIC RECOMBINANT ANTIBODIES | |
JP2002531466A5 (en) | ||
DE69232944T2 (en) | Modified immunoglobulins for specific FC-Epsilon receptors | |
JP3095175B2 (en) | Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma | |
DE69605181T3 (en) | ANTIBODIES TO CD30 PREVENT PROTEOLYTIC CLEAVAGE AND DELIVERY OF MEMBRANEOUS CD30 ANTIGEN | |
RU96115107A (en) | "HUMAN" ANTIBODIES AND THEIR USE | |
US20040052783A1 (en) | Humanized antibodies against CD3 | |
EP0749488A1 (en) | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders | |
Leger et al. | Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. | |
KR920702425A (en) | CDR-grafted anti-CEA antibodies and their preparation | |
DE60217698T2 (en) | TREATMENT OF CHRONIC RADIATION IGNITION USING AN ANTIBODY AGAINST THE CD3 ANTIGEN COMPLEX | |
DE69006337D1 (en) | Chimeric antibodies for the detection and therapy of infectious and inflammatory lesions. | |
CN102711829A (en) | Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) | |
NZ314793A (en) | Humanised immunoglobulins; production and use to manufacture a medicament, polynucleotides and cell lines | |
CA2223491A1 (en) | Cdr-grafted anti-tissue factor antibodies and methods of use thereof | |
CN107148281A (en) | With reference to CXCR5 antigen-binding proteins | |
ES2307301T3 (en) | ANTIBODY LO-CD2a AND USES OF THE SAME TO INHIBIT THE ACTIVATION AND PROLIFERATION OF CELLS T. | |
US20110002925A1 (en) | Use of Anti-IL-20 Antibody for Treating Rheumatoid Arthritis and Osteoporosis | |
US20020110558A1 (en) | Use of CD25 binding molecules in the treatment of rheumatoid arthritis or skin diseases | |
Van Assche et al. | Novel Biological Agents for the Treatment of Ulcerative Colitis |